An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

By A. Fung, Geeta A. Lalwani, P. Rosenfeld, Sander R. Dubovy, S. Michels, W. Feuer, C. Puliafito, Janet L. Davis, H. Flynn, Maria Esquiabro. American journal of ophthalmology-glaucoma, 2007

1,010 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/ebdf7fc6b97ce73b9d9fd99d0700d3c61ce0899d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Geeta A. Lalwani
2. P. Rosenfeld
3. A. Fung
4. Sander R. Dubovy
5. S. Michels
6. W. Feuer
7. Janet L. Davis
8. H. Flynn

Citations in the corpus

• A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. (2009, methodology): “RAPHY THROUGH 24 MONTHS: The 1-year results of the PrONTO Study were reported previously.(7) Noteworthy outcomes included an improvement in VA detectable by day 14 and increases in mean and median VA scores at month 3 of 10.”